中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2014年
8期
1697-1699
,共3页
瑞芬太尼%皮瓣缺血%再灌注损伤%Toll样受体4%核因子-κB
瑞芬太尼%皮瓣缺血%再灌註損傷%Toll樣受體4%覈因子-κB
서분태니%피판결혈%재관주손상%Toll양수체4%핵인자-κB
Remifentanil%Flap ischemia%Reperfusion injury%Toll-like receptor 4%Nuclear factor-κB
目的 探讨瑞芬太尼在皮瓣缺血再灌注损伤中的作用及机制.方法 将80只雄性SD大鼠随机分为:假手术组(20只)、缺血再灌注(I/R)组(20只)、瑞芬太尼组(20只)、Toll样受体4(TLR4)抑制剂组(20只).制备皮瓣I/R模型.瑞芬太尼组和TLR4抑制剂组于再灌注前静脉注射瑞芬太尼1 μg/(kg· min)和E5564(5 mg/kg),分别于缺血再灌注后2、4、8h,采用实时定量聚合酶链反应(Real-time PCR)和Western blot检测TLR4和核因子-κB (NF-κB)在皮瓣组织中的表达.于术后7d,应用图像分析软件计算皮瓣存活比例.结果 Real-time PCR和Western blot检测显示I/R组比瑞芬太尼组和TLR4抑制组TLR4及NF-κB表达明显增强.瑞芬太尼组和TLR4抑制组再灌注后TLR4和NF-κB活性受到抑制.术后7dI/R组、瑞芬太尼组和TLR4抑制剂组皮瓣存活比例分别为(61.40±7.12)％、(80.31±11.63)％和(82.10±10.21)％,与I/R组比较差异有统计学意义(P＜0.05).结论 瑞芬太尼可以通过抑制TLR4表达及减少NF-κB活化,减轻皮瓣缺血再灌注损伤.
目的 探討瑞芬太尼在皮瓣缺血再灌註損傷中的作用及機製.方法 將80隻雄性SD大鼠隨機分為:假手術組(20隻)、缺血再灌註(I/R)組(20隻)、瑞芬太尼組(20隻)、Toll樣受體4(TLR4)抑製劑組(20隻).製備皮瓣I/R模型.瑞芬太尼組和TLR4抑製劑組于再灌註前靜脈註射瑞芬太尼1 μg/(kg· min)和E5564(5 mg/kg),分彆于缺血再灌註後2、4、8h,採用實時定量聚閤酶鏈反應(Real-time PCR)和Western blot檢測TLR4和覈因子-κB (NF-κB)在皮瓣組織中的錶達.于術後7d,應用圖像分析軟件計算皮瓣存活比例.結果 Real-time PCR和Western blot檢測顯示I/R組比瑞芬太尼組和TLR4抑製組TLR4及NF-κB錶達明顯增彊.瑞芬太尼組和TLR4抑製組再灌註後TLR4和NF-κB活性受到抑製.術後7dI/R組、瑞芬太尼組和TLR4抑製劑組皮瓣存活比例分彆為(61.40±7.12)％、(80.31±11.63)％和(82.10±10.21)％,與I/R組比較差異有統計學意義(P＜0.05).結論 瑞芬太尼可以通過抑製TLR4錶達及減少NF-κB活化,減輕皮瓣缺血再灌註損傷.
목적 탐토서분태니재피판결혈재관주손상중적작용급궤제.방법 장80지웅성SD대서수궤분위:가수술조(20지)、결혈재관주(I/R)조(20지)、서분태니조(20지)、Toll양수체4(TLR4)억제제조(20지).제비피판I/R모형.서분태니조화TLR4억제제조우재관주전정맥주사서분태니1 μg/(kg· min)화E5564(5 mg/kg),분별우결혈재관주후2、4、8h,채용실시정량취합매련반응(Real-time PCR)화Western blot검측TLR4화핵인자-κB (NF-κB)재피판조직중적표체.우술후7d,응용도상분석연건계산피판존활비례.결과 Real-time PCR화Western blot검측현시I/R조비서분태니조화TLR4억제조TLR4급NF-κB표체명현증강.서분태니조화TLR4억제조재관주후TLR4화NF-κB활성수도억제.술후7dI/R조、서분태니조화TLR4억제제조피판존활비례분별위(61.40±7.12)％、(80.31±11.63)％화(82.10±10.21)％,여I/R조비교차이유통계학의의(P＜0.05).결론 서분태니가이통과억제TLR4표체급감소NF-κB활화,감경피판결혈재관주손상.
Objective To investigate the function and mechanism of remifentanil in flap ischemiareperfusion injury (IRI).Methods A totol of 80 adult male SD rats were randomly divided into 4 groups:sham-operated group (n =20),IRI group (n =20),remifentanil group (n =20) and Toll-like receptor 4 (TLR4) inhibitor group (n＝20).Flap IRI model was established.Remifentanil group and TLR4 inhibitor group before reperfusion were intravenously injected with remifentanil 1 μg/(kg· min) and E5564 (5 mg/kg),respectively.At 2,4 and 8 h after I/R,real-time quantitative polymerase chain reaction (Real-time PCR) and Western blotting were applied to detect the expression of TLR4 and nuclear factor-κB (NF-κB) in the flap tissue.On the postoperative day 7,image analysis software was used to calculate flap survival rate.Results The Real-time PCR and Western blotting showed that the expression of TLR4 and NF-κB was significantly enhanced in IRI group as compared with remifentanil group and TLR4 inhibitor group.The expression of TLR4 and NF-κB was inhibited after reperfusion in remifentanil group and TLR4 inhibitor group.On the postoperative day 7,the flap survival rate in IRI group,remifentanil group and TLR4 inhibitor group was (61.40 ±7.12)％,(80.31 ± 11.63)％ and (82.10 ± 10.21)％ respectively,and there was significant difference between IRI group and remifentanil group or TLR4 inhibitor group (P ＜ 0.05 for both).Conclusion Remifentanil may alleviate flap IRI by inhibiting TLR4 expression and activation of NF-κB.
